{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:27:37Z","timestamp":1768314457031,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","revespcardiol.org","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.rec.2018.05.003","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T21:23:42Z","timestamp":1529616222000},"page":"1027-1035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain"],"prefix":"10.1016","volume":"71","author":[{"given":"Antonio","family":"Olry de Labry Lima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Gimeno Ballester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Francisco","family":"Sierra S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Matas Hoces","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Gonz\u00e1lez-Out\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio Jes\u00fas","family":"Alegre del Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rec.2018.05.003_bib0225","unstructured":"OMS: Organizaci\u00f3n Mundial de la Salud. Informe sobre la situaci\u00f3n mundial de las enfermedades no transmisibles 2010. Available at:: http:\/\/www.who.int\/nmh\/publications\/ncd_report2010\/es\/. Accessed 2 Oct 2017."},{"key":"10.1016\/j.rec.2018.05.003_bib0230","first-page":"CD011748","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","volume":"4","author":"Schmidt","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.rec.2018.05.003_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2018.05.003_bib0240","unstructured":"A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of alirocumab on the occurrence of cardiovascular events in patients who have recently experienced an acute coronary syndrome. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01663402. Accessed 29 Aug 2017."},{"key":"10.1016\/j.rec.2018.05.003_bib0245","unstructured":"National Institute for Health and Care Excellence. Putting NICE guidance into practice. Resource impact report: Alirocumab (TA393) and evolocumab (TA394) for treating primary hypercholesterolaemia and mixed dyslipidaemia. National Institute for Health and Care Excellence. 2016. Available at: https:\/\/www.nice.org.uk\/guidance\/ta394\/resources\/resource-impact-report-pdf-2543362381. Accessed 2 Aug 2017."},{"key":"10.1016\/j.rec.2018.05.003_bib0250","unstructured":"National Institute for Health and Care Excellence. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. Available at: https:\/\/www.nice.org.uk\/guidance\/ta394. Accessed 2 Aug 2017."},{"key":"10.1016\/j.rec.2018.05.003_bib0255","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.gaceta.2010.02.006","article-title":"Los modelos de Markov probabil\u00edsticos en la evaluaci\u00f3n de tecnolog\u00edas sanitarias: una gu\u00eda pr\u00e1ctica","volume":"24","author":"Mar","year":"2010","journal-title":"Gac Sanit."},{"key":"10.1016\/j.rec.2018.05.003_bib0260","unstructured":"Bot Plus 2.0. Consejo General de Colegios Oficiales de Farmac\u00e9uticos. https:\/\/botplusweb.portalfarma.com\/botplus.aspx. Accessed 8 Sep 2017."},{"key":"10.1016\/j.rec.2018.05.003_bib0265","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.clinthera.2017.02.011","article-title":"Cost-effectiveness of evolocumab in patients with high cardiovascular risk in Spain","volume":"39","author":"Villa","year":"2017","journal-title":"Clin Ther."},{"key":"10.1016\/j.rec.2018.05.003_bib0270","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s12325-015-0252-y","article-title":"Prevalence, treatment, and control of hypercholesterolemia in high cardiovascular risk patients: evidences from a systematic literature review in Spain","volume":"32","author":"De la Sierra","year":"2015","journal-title":"Adv Ther."},{"key":"10.1016\/j.rec.2018.05.003_bib0275","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jacl.2017.01.002","article-title":"Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia","volume":"11","author":"L\u00e1zaro","year":"2017","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.rec.2018.05.003_bib0280","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad. Costes hospitalarios-Contabilidad Anal\u00edtica. Available at: https:\/\/www.msssi.gob.es\/estadEstudios\/estadisticas\/inforRecopilaciones\/anaDesarrolloGDR.htm. Accessed 29 Jul 2017."},{"key":"10.1016\/j.rec.2018.05.003_bib0285","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.aprim.2013.12.015","article-title":"Diagn\u00f3stico y tratamiento de la hipercolesterolemia familiar en Espa\u00f1a: documento de consenso","volume":"47","author":"Mata","year":"2015","journal-title":"Aten Primaria."},{"key":"10.1016\/j.rec.2018.05.003_bib0290","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF03320900","article-title":"Principios, m\u00e9todos y aplicaciones del an\u00e1lisis del impacto presupuestario en el sector sanitario","volume":"2","author":"Brosa","year":"2005","journal-title":"PharmacoEconomics Spanish Research Articles."},{"key":"10.1016\/j.rec.2018.05.003_bib0295","first-page":"211","article-title":"Epidemiolog\u00eda de la enfermedad vascular cerebral en Espa\u00f1a","volume":"25","author":"Brea","year":"2013","journal-title":"Clin Invest Arterioscl."},{"key":"10.1016\/j.rec.2018.05.003_bib0300","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1157\/13048156","article-title":"La prevenci\u00f3n secundaria de la enfermedad coronaria es menos agresiva en los pacientes de m\u00e1s de 64 a\u00f1os","volume":"56","author":"Mu\u00f1oz","year":"2003","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2018.05.003_bib0305","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.recesp.2012.03.008","article-title":"Prevalencia y caracter\u00edsticas cl\u00ednicas de la enfermedad arterial perif\u00e9rica en la poblaci\u00f3n general del estudio Hermex","volume":"65","author":"F\u00e9lix-Redondo","year":"2012","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2018.05.003_bib0310","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.recesp.2015.12.022","article-title":"Prevalencia y pron\u00f3stico de los pacientes con infarto de miocardio de alto riesgo candidatos a doble tratamiento antiagregante prolongado","volume":"69","author":"Marrugat","year":"2016","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2018.05.003_bib0315","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.recesp.2014.09.019","article-title":"Prevalencia de angina estable en Espa\u00f1a. Resultados del estudio OFRECE","volume":"68","author":"Alonso","year":"2015","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2018.05.003_bib0320","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejvs.2009.04.013","article-title":"Prevalence of symptomatic and asymptomatic peripheral arterial disease and the value of the ankle-brachial index to stratify cardiovascular risk","volume":"38","author":"Ramos","year":"2009","journal-title":"Eur J Vasc Endovasc Surg."},{"issue":"B","key":"10.1016\/j.rec.2018.05.003_bib0325","first-page":"3","article-title":"Epidemiolog\u00eda de la angina estable","volume":"10","author":"Bonet Basiero","year":"2010","journal-title":"Rev Esp Cardiol Supl."},{"key":"10.1016\/j.rec.2018.05.003_bib0330","unstructured":"Instituto Nacional de Estad\u00edstica. Proyecciones de poblaci\u00f3n a corto plazo. Available at: http:\/\/www.ine.es\/jaxi\/menu.do?type=pcaxis&path=\/t20\/p269&file=inebase. Accessed 8 Jun 2017."},{"key":"10.1016\/j.rec.2018.05.003_bib0335","unstructured":"Real Decreto-ley 8\/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. Bolet\u00edn Oficial del Estado, 24 de mayo de 2010. Available at: https:\/\/www.boe.es\/boe\/dias\/2010\/05\/24\/pdfs\/BOE-A-2010-8228.pdf. Accessed 8 Sep 2017."},{"key":"10.1016\/j.rec.2018.05.003_bib0340","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","article-title":"Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias","volume":"24","author":"L\u00f3pez Bastida","year":"2010","journal-title":"Gac Sanit."},{"key":"10.1016\/j.rec.2018.05.003_bib0345","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol."},{"key":"10.1016\/j.rec.2018.05.003_bib0350","unstructured":"Jackson C. Flexsurv: Flexible parametric survival and multi-state models. 2014. Available at: https:\/\/cran.r-project.org\/. Accessed 28 Sep 2017."},{"key":"10.1016\/j.rec.2018.05.003_bib0355","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","article-title":"Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease","volume":"2","author":"Fonarow","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.rec.2018.05.003_bib0360","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA."},{"key":"10.1016\/j.rec.2018.05.003_bib0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-016-0302-8","article-title":"Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center","volume":"15","author":"Shah","year":"2016","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.rec.2018.05.003_bib0370","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jamacardio.2017.3655","article-title":"Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial","volume":"2","author":"Arrieta","year":"2017","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.rec.2018.05.003_bib0375","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jama.2017.9924","article-title":"Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial","volume":"318","author":"Kazi","year":"2017","journal-title":"JAMA."},{"key":"10.1016\/j.rec.2018.05.003_bib0380","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1001\/jama.283.15.2013","article-title":"Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"283","author":"Lasagna","year":"2000","journal-title":"JAMA."},{"key":"10.1016\/j.rec.2018.05.003_bib0385","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.metabol.2003.07.020","article-title":"Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type2 diabetes mellitus","volume":"53","author":"Abbasi","year":"2004","journal-title":"Metabolism."},{"key":"10.1016\/j.rec.2018.05.003_bib0390","first-page":"548","article-title":"Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature","volume":"69","author":"Ebell","year":"2004","journal-title":"Am Fam Physician."},{"key":"10.1016\/j.rec.2018.05.003_bib0395","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.recesp.2015.11.016","article-title":"M\u00e1xima reducci\u00f3n de colesterol unido a lipoprote\u00ednas de baja densidad alcanzable con combinaciones farmacol\u00f3gicas. Cuando 50 m\u00e1s 20 suma 60","volume":"69","author":"Masana l","year":"2016","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2018.05.003_bib0400","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/heartjnl-2016-310844","article-title":"PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?","volume":"103","author":"Hadjiphilippou","year":"2017","journal-title":"Heart."},{"key":"10.1016\/j.rec.2018.05.003_bib0405","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad. Informe de Posicionamiento Terap\u00e9utico de evolocumab (Repatha\u00ae) en hipercolesterolemia 2016. Available at: https:\/\/www.aemps.gob.es\/en\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-evolocumab-repatha.pdf. Accessed 1 Jun 2017."},{"key":"10.1016\/j.rec.2018.05.003_bib0410","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad. Informe de Posicionamiento Terap\u00e9utico de alirocumab (Praluent\u00ae) en hipercolesterolemia 2016. Available at: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-alirocumab-Praluent-hipercolesterolemia.pdf. Accessed 1 Jun 2017."},{"key":"10.1016\/j.rec.2018.05.003_bib0415","first-page":"164","article-title":"Documento de consenso de la Sociedad Espa\u00f1ola de Arteriosclerosis sobre las indicaciones de los inhibidores de la PCSK9","volume":"28","author":"Masana","year":"2016","journal-title":"Clin Invest Arterioscl."},{"key":"10.1016\/j.rec.2018.05.003_bib0420","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40273-017-0492-6","article-title":"Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: an evidence review group perspective of a NICE single technology appraisal","volume":"35","author":"Carroll","year":"2017","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.rec.2018.05.003_bib0425","unstructured":"National Institute for Health and Care Excellence. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. Available at: https:\/\/www.nice.org.uk\/guidance\/ta393. Accessed 2 Aug 2017."},{"key":"10.1016\/j.rec.2018.05.003_bib0430","first-page":"182","article-title":"Consenso de expertos sobre la detecci\u00f3n y el manejo cl\u00ednico de la hipercolesterolemia familiar","volume":"25","author":"Masana","year":"2013","journal-title":"Clin Invest Arterioscl."},{"key":"10.1016\/j.rec.2018.05.003_bib0435","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11883-012-0291-7","article-title":"How do we improve patient compliance and adherence to long-term statin therapy?","volume":"15","author":"Maningat","year":"2013","journal-title":"Curr Atheroscler Rep."},{"key":"10.1016\/j.rec.2018.05.003_bib0440","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","article-title":"Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review","volume":"78","author":"De Vera","year":"2014","journal-title":"Br J Clin Pharmacol."}],"updated-by":[{"DOI":"10.1016\/j.rec.2018.05.044","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000}}],"container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585718301877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585718301877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T11:51:24Z","timestamp":1543319484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585718301877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1885585718301877"],"URL":"https:\/\/doi.org\/10.1016\/j.rec.2018.05.003","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.rec.2018.05.044","asserted-by":"object"}]},"ISSN":["1885-5857"],"issn-type":[{"value":"1885-5857","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2018.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2018.05.044","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.recesp.2018.02.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedad Espa\u00f1ola de Cardiolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}